ARQT
Price
$31.18
Change
+$1.22 (+4.07%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
3.67B
89 days until earnings call
Intraday BUY SELL Signals
IMMX
Price
$4.84
Change
+$0.69 (+16.63%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
139.35M
83 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs IMMX

Header iconARQT vs IMMX Comparison
Open Charts ARQT vs IMMXBanner chart's image
Arcutis Biotherapeutics
Price$31.18
Change+$1.22 (+4.07%)
Volume$50.79K
Capitalization3.67B
Immix Biopharma
Price$4.84
Change+$0.69 (+16.63%)
Volume$14.28K
Capitalization139.35M
ARQT vs IMMX Comparison Chart in %
ARQT
Daily Signal:
Gain/Loss:
IMMX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARQT vs. IMMX commentary
Dec 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and IMMX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 05, 2025
Stock price -- (ARQT: $29.96 vs. IMMX: $4.15)
Brand notoriety: ARQT and IMMX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 71% vs. IMMX: 72%
Market capitalization -- ARQT: $3.67B vs. IMMX: $139.35M
ARQT [@Biotechnology] is valued at $3.67B. IMMX’s [@Biotechnology] market capitalization is $139.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileIMMX’s FA Score has 0 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • IMMX’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARQT and IMMX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 4 TA indicator(s) are bullish while IMMX’s TA Score has 3 bullish TA indicator(s).

  • ARQT’s TA Score: 4 bullish, 4 bearish.
  • IMMX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than IMMX.

Price Growth

ARQT (@Biotechnology) experienced а -3.23% price change this week, while IMMX (@Biotechnology) price change was -3.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.21%. For the same industry, the average monthly price growth was +5.86%, and the average quarterly price growth was +56.03%.

Reported Earning Dates

ARQT is expected to report earnings on Mar 03, 2026.

IMMX is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (+1.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARQT($3.67B) has a higher market cap than IMMX($139M). ARQT YTD gains are higher at: 115.075 vs. IMMX (88.636). IMMX has higher annual earnings (EBITDA): -23.58M vs. ARQT (-68.35M). ARQT has more cash in the bank: 191M vs. IMMX (11.6M). IMMX has less debt than ARQT: IMMX (1.04M) vs ARQT (110M). ARQT has higher revenues than IMMX: ARQT (263M) vs IMMX (0).
ARQTIMMXARQT / IMMX
Capitalization3.67B139M2,640%
EBITDA-68.35M-23.58M290%
Gain YTD115.07588.636130%
P/E RatioN/AN/A-
Revenue263M0-
Total Cash191M11.6M1,647%
Total Debt110M1.04M10,547%
FUNDAMENTALS RATINGS
ARQT: Fundamental Ratings
ARQT
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
PROFIT vs RISK RATING
1..100
76
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARQTIMMX
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 25 days ago
84%
Declines
ODDS (%)
Bearish Trend 22 days ago
88%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARQT
Daily Signal:
Gain/Loss:
IMMX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SMECX9.290.11
+1.20%
Invesco Small Cap Equity C
PEMGX43.500.35
+0.81%
Principal MidCap A
DRIPX31.090.23
+0.75%
The MP 63
FTVAX32.520.22
+0.68%
FullerThaler Behav Md-Cp Val A
MSOPX32.250.17
+0.53%
Morgan Stanley Inst Global Opp C

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with IDYA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
+1.80%
IDYA - ARQT
44%
Loosely correlated
+1.93%
NUVL - ARQT
43%
Loosely correlated
+1.85%
WVE - ARQT
43%
Loosely correlated
+2.15%
BEAM - ARQT
42%
Loosely correlated
+14.42%
NRIX - ARQT
42%
Loosely correlated
+2.94%
More

IMMX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMMX has been loosely correlated with PRQR. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMMX jumps, then PRQR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMMX
1D Price
Change %
IMMX100%
+4.53%
PRQR - IMMX
38%
Loosely correlated
+3.08%
IMTX - IMMX
34%
Loosely correlated
+4.55%
ARQT - IMMX
34%
Loosely correlated
+1.80%
CMMB - IMMX
34%
Loosely correlated
-1.58%
SRRK - IMMX
33%
Loosely correlated
+5.92%
More